José Luis Molinuevo

Neurologist, Scientific Director of the Alzheimer's Prevention Program at the BarcelonaBeta Brain Research Center (BBRC)

José Luis Molinuevo

Neurologist, Scientific Director of the Alzheimer's Prevention Program at the BarcelonaBeta Brain Research Center (BBRC)

Neurologist; his clinical work and research activities are related with neurodegenerative diseases, mostly Alzheimer’s disease (AD) and related disorders. He undertook his MD degree at the University of Valencia, his neurology training at Hospital Clinic in Barcelona, and his PhD, on Parkinson’s disease, at the University of Barcelona. He directed the Alzheimer’s disease and other cognitive disorders unit at the Hospital Clinic de Barcelona since 2003, which includes a genetic counselling program for monogenic dementias (PICOGEN) until 2016. He joined the Barcelonabeta Brain Research Center (BBRC) in 2014, where he is the Scientific Director of the Alzheimer Prevention Program and University Pompeu Fabra in 2018 as associate professor. BBRC is mainly dedicated to research on Alzheimer’s disease (AD) prevention from a clinical, cognitive, genetic, and biomarker, including wet and neuroimaging, perspective.

He is a member of the European Alzheimer Disease Consortium, of the dementia panel for the European Association of Neurology, of the Alzheimer Biomarker Standarization Initiative (ABSI), the Spanish coordinator of the BIOMARKAPD of the Joint Programming on Neurodegenerative Diseases, partner of several Innovative Medicine Initiative consortiums and part of the AD International Working Group, Subjective Cognitive Decline Initiative (SCD-I) Working Group and the NIA-AA network for developing new research criteria.

He is principal investigator of multiple clinical trials and research studies on AD and, with an h-index of 58, he has published over 320 international scientific papers that have been cited 14210+ times, several books and over 20 book chapters on neurodegenerative diseases (database: SCOPUS). He has been part of the board of directors of the Spanish Neurological Society from 2000-2002, has coordinated the dementia scientific group from 2006-2008 and awarded with the 2010 AD scientific prize of the Spanish Neurological Society. In addition, he has provided scientific advice or has been an investigator or data monitoring board member for Novartis, Pfizer, Eisai, Janssen-Cilag, Lundbeck, Roche, Genentech, Bayer, Bristol-Myers Squibb, GE Health Care, Merz, MSD, GlaxoSmithKline, Astra-Zeneca, Avid, Lilly, Boehringer-Inghelmein, Biokit, Piramal, IBL and Fujireibio-Europe.

All sessions by José Luis Molinuevo

Título/Title

22 May 2020
09:30 - 09:45

EPAD

22 May 2020
10:30 - 10:45